Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
REVENUES:    
Product revenue, net $ 2,429 $ 2,482
COSTS AND EXPENSES:    
Cost of sales 943 1,660
Research and development 7,436 12,863
General and administrative 10,104 9,310
Total operating expenses 18,483 23,833
Operating loss (16,054) (21,351)
Grant income 923
Gain on change in fair value of warrant liabilities 7,005
Loss on extinguishment of debt (2,092)
Other income (expense), net 394 (593)
Net loss available to common stockholders $ (16,829) $ (14,939)
Net loss per common share, basic $ (2.84) $ (535.72)
Net loss per common share, diluted $ (2.84) $ (535.72)
Weighted average common shares outstanding, basic 5,927,231 27,886
Weighted average common shares outstanding, diluted 5,927,231 27,886